Category: Uncategorized

MD-Level Note: Steroid Dosing in Nephrotic Syndrome

checking oedema in nephrotic syndrome

1. Standard (First Episode) Nephrotic Syndrome

Guideline Reference:

• KDIGO 2021 Glomerular Disease Guideline

• IPNA Consensus 2021

• Nelson Textbook of Pediatrics (22nd ed., Ch. 494, p. 2570)

Dose:

Prednisolone 2 mg/kg/day (maximum 60 mg/day) for 6 weeks, followed by
1.5 mg/kg on alternate days (maximum 40 mg) for next 6 weeks.

Rationale:

• Earlier protocols (e.g., 4+4 week or 8-week total) are less effective.

• Prolonged 12-week regimen (6+6) gives fewer relapses.

Practical Example 1:

A 20 kg child presents with first episode NS.

• Daily dose: 2 mg/kg = 40 mg daily × 6 weeks.

• Then alternate-day: 1.5 mg/kg = 30 mg on alternate days × 6 weeks.

• Total course: 12 weeks.

Avoid: tapering below alternate day dose before completion of 12 weeks — increases relapse.

2. Relapsing Nephrotic Syndrome

a. Infrequent Relapser

• <2 relapses in 6 months or <3 in 1 year.

Dose:

Prednisolone 2 mg/kg/day until remission (urine protein nil/trace × 3 days),
then 1.5 mg/kg on alternate days for 4 weeks, then stop.

Example:
Child relapses after 5 months remission → give daily 2 mg/kg till protein nil ×3 days → shift to 1.5 mg/kg AD ×4 weeks → stop.

b. Frequent Relapser

• ≥2 relapses in 6 months or ≥4 in 12 months.

Dose:
Same as above for each relapse, but consider tapering or steroid-sparing agent.

Maintenance (if steroid-only used):

Alternate day 0.5–0.7 mg/kg prednisolone for 3–6 months.

Example:
If child relapses every 2 months — after inducing remission, maintain on 0.5 mg/kg AD for 6 months to break cycle.

c. Steroid-Dependent Nephrotic Syndrome (SDNS)

• Relapse during tapering or within 2 weeks of stopping steroids.

Strategy 1: Low-dose alternate-day steroids

Maintain remission with 0.3–0.5 mg/kg AD for 6–12 months.

Strategy 2: Add steroid-sparing agent

Cyclophosphamide, levamisole, MMF, or calcineurin inhibitor depending on toxicity and previous exposure.

Example:
A 7-year-old develops relapse each time dose falls below 0.5 mg/kg AD → maintain at 0.5 mg/kg AD × 6 months; if Cushingoid, add levamisole.

d. Steroid-Resistant Nephrotic Syndrome (SRNS)

• No remission after 6 weeks of daily 2 mg/kg prednisolone.

Confirm compliance, dose accuracy, and rule out secondary NS before labeling SRNS.

Protocol:

Continue same dose for total 6–8 weeks before biopsy and calcineurin inhibitor introduction.

Example:
A 6-year-old on pred 2 mg/kg × 6 weeks still 3+ protein — if compliance ensured, classify as SRNS, proceed to biopsy.

3. Partial Responders or Slow Responders

If urine protein reduces but not nil after 6 weeks →
continue full dose 2 mg/kg/day for additional 2 weeks before deciding resistance.

4. Relapse While on Alternate-Day Therapy

Switch to 2 mg/kg/day until remission × 3 days,
then back to alternate-day baseline dose for 4 weeks.

5. Relapse While on Daily Steroid (e.g., during infection)

Do not increase dose; continue same daily dose until infection settles.
After remission, taper normally.

6. Special Scenarios

a. Grossly Edematous Child

• Use IV methylprednisolone (10–15 mg/kg/day × 3 days) if poor oral absorption suspected, then switch to oral 2 mg/kg/day.

• Confirm no hypovolemia before diuretics.

b. Infantile Nephrotic Syndrome (<1 yr)

• Usually genetic; steroid trial limited: 2 mg/kg/day × 6 weeks, but if no response by 4 weeks, stop (to avoid toxicity).

c. Secondary NS (e.g., lupus, infection-related)

• Dosing guided by underlying disease.

• Lupus NS: 2 mg/kg/day (max 60 mg) × 4 weeks + taper; or IV methylpred pulses.

7. Tapering Protocols – Practical Pearls

Avoid abrupt stop:

Always taper after alternate-day phase, not during daily phase.

Example – Extended taper for high-risk relapser:

After 6+6 weeks:

• Reduce to 1 mg/kg AD × 2 weeks

• Then 0.5 mg/kg AD × 2 weeks

• Then stop.

Taper traps:

8. Toxicity Prevention

9. Transition to Steroid-Sparing Agents (for practice)

10. Practical MD-Level Scenarios & Solutions

11. Key Pharmacologic Notes

• Bioavailability: Prednisolone preferred (not deflazacort for initial induction).

• Equivalent doses: 5 mg prednisolone = 4 mg methylpred = 0.75 mg dexamethasone.

• Morning dosing preferable to preserve circadian rhythm.

12. Reference Sources

1. Kliegman RM, Nelson Textbook of Pediatrics, 22nd ed., Elsevier, 2023.

2. KDIGO Glomerular Diseases Guideline, 2021.

3. Indian Pediatrics Nephrology Group, Consensus Statement on Management of Nephrotic Syndrome, 2021.

4. IPNA Clinical Practice Recommendations for Idiopathic NS, 2020.

5. Avner ED et al., Pediatric Nephrology, 8th ed. (RPS, 2022).

Table of Contents(toc)

When a young child comes in with cough, difficulty breathing, and fever, one of the most important — and sometimes confusing — clinical questions is:

Is this bronchiolitis, pneumonia, or something else entirely?

1. Age and Season — The First Clues

According to Nelson, bronchiolitis is primarily a disease of infants, typically below 2 years of age, with the peak incidence between 2–6 months. It usually appears during the winter and early spring months, corresponding to RSV season.

Pneumonia, on the other hand, can occur in all age groups. Viral pneumonias are more common in infants and preschoolers, while bacterial pneumonias increase with age. There’s no strict seasonal restriction, though viral etiologies may peak in winter.

2. Etiology — The Culprit Behind It

• Bronchiolitis:
  Caused most commonly by Respiratory Syncytial Virus (RSV) — responsible for the majority of cases in infants. Other causes include parainfluenza, influenza, human metapneumovirus, and adenovirus.

• Pneumonia:

  • Viral — RSV, influenza, parainfluenza, adenovirus.

  • Bacterial — Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Mycoplasma pneumoniae (in older children).

In short, RSV = bronchiolitis, while bacterial pathogens = pneumonia is a good starting point, though overlap exists.

3. Pathophysiology — Where the Problem Lies

Nelson emphasizes that the site of pathology differentiates the two:

• Bronchiolitis: Inflammation and edema of small airways (bronchioles) → obstruction → air trapping, atelectasis, and wheeze.

• Pneumonia: Involves alveoli → consolidation, impaired gas exchange, and reduced compliance.

So, in bronchiolitis, the problem is in airflow, whereas in pneumonia, it’s in oxygen exchange.

4. Clinical Features — The Real Diagnostic Key

In bronchiolitis, wheezing and hyperinflation dominate; in pneumonia, crackles and focal findings dominate.

5. Chest X-ray — Helpful but Not Always Diagnostic

Nelson advises that radiologic findings should not be used in isolation to differentiate.
However, classic patterns help:

• Bronchiolitis: Hyperinflated lungs, flattened diaphragm, peribronchial thickening, patchy atelectasis — no focal consolidation.

• Pneumonia: Lobar or segmental consolidation, air bronchograms, or patchy infiltrates.

6. Response to Therapy

Another practical clue from Nelson:

• Bronchiolitis: Poor response to antibiotics; supportive care is the mainstay (hydration, oxygen if hypoxemic).

• Pneumonia: Marked improvement with appropriate antibiotics if bacterial.

7. Common Differentials (Nelson Mentions)

Nelson lists several conditions that mimic bronchiolitis or pneumonia:

1. Asthma (viral-induced wheeze):

   • Often recurrent episodes.

   • Family/personal history of atopy or asthma.

   • Responds well to bronchodilators, unlike classic bronchiolitis.

2. Pertussis:

   • Paroxysmal cough, inspiratory “whoop,” vomiting after coughing.

   • Minimal wheeze, may have leukocytosis with lymphocytosis.

3. Foreign Body Aspiration:

   • Sudden onset, unilateral decreased air entry, localized hyperinflation or collapse.

4. Congestive Heart Failure:

   • Tachypnea, hepatomegaly, but no true wheezing unless pulmonary edema present.

   • Cardiomegaly on chest X-ray.

5. Aspiration Pneumonitis / GER-related:

   • History of vomiting, feeding difficulty, neurological disease.

   • Recurrent or persistent infiltrates in dependent lung areas.

8. Management Overview (as per Nelson)

• Bronchiolitis:

  • Supportive: Oxygen, hydration, nasal suctioning.

  • Avoid routine bronchodilators, steroids, antibiotics.

  • Hospitalization: If severe distress, apnea, poor feeding, or SpO₂ < 90%.

• Pneumonia:

  • Empiric antibiotics based on age and likely pathogen.

  • Supportive care: Oxygen, fluids, antipyretics.

9. Key Takeaway from Nelson

“Bronchiolitis should be suspected in infants with their first episode of wheezing following a viral prodrome, whereas pneumonia should be suspected in the presence of fever, focal crackles, and signs of consolidation.”

In practice, overlap exists — especially when viral pneumonia blurs the line — but understanding age, pattern, and auscultatory findings helps steer the diagnosis right.

10. Summary Table

References

• Nelson Textbook of Pediatrics, 21st Edition, Chapters 390 (Bronchiolitis) and 391 (Pneumonia).

• Nelson Essentials of Pediatrics, 9th Edition, Section: Respiratory Disorders in Children.

Umbilical Vein Catheterization (UVC) Notes for Medical students and Graduates

a child with umbilical vein catheter insitu cc by 4 wikimedia

Purpose:

• For vascular access in neonates (especially preterm or critically ill).

• Used for fluid, blood, medication administration, exchange transfusion, and central venous pressure (CVP) monitoring.

Indications

• Emergency vascular access in neonates

• Exchange transfusion

• Administration of IV fluids, parenteral nutrition, inotropes, or antibiotics

• Blood sampling or transfusion

• Monitoring of central venous pressure

Contraindications

• Omphalitis or periumbilical infection

• Peritonitis

• Necrotizing enterocolitis (NEC)

• Umbilical or portal vein thrombosis

• Imperforate or absent umbilical vein

Anatomical Background

• Umbilical vein: single, large, thin-walled vessel at 12 o’clock position in the umbilical stump.

• Leads to left portal vein → ductus venosus → inferior vena cava.

• Two smaller umbilical arteries at 4 and 8 o’clock positions.

Equipment

• Sterile gloves, drapes, antiseptic solution

• Umbilical catheter (3.5 Fr for <1.5 kg, 5 Fr for >1.5 kg)

• Sterile scissors, forceps, and sutures

• 3-way stopcock and syringes

• Normal saline for flush

• Adhesive tape and umbilical tie

• Sterile dressing

Procedure Steps

1. Preparation

• Maintain aseptic technique.

• Place baby under radiant warmer.

• Monitor heart rate, SpO₂, and temperature.

• Restrain limbs gently.

2. Identify Vessels

• Clean umbilical stump with antiseptic.

• Trim cord to ~1–2 cm from skin margin.

• Identify one large thin-walled umbilical vein (12 o’clock) and two smaller thick-walled arteries (4 and 8 o’clock).

3. Catheter Measurement

• Measure insertion length:

  • Formula (Shukla’s):
    [
    Length (cm) = (3 × weight [kg]) + 9 text{ cm (for term)}
    ]
    or
    [
    Length (cm) = (1.5 × birthweight [kg]) + 5.6 text{ cm (for preterm)}
    ]

  • Aim: tip at IVC–right atrial junction (high position).

4. Catheter Insertion

• Tie umbilical tape loosely at the base of the cord.

• Gently dilate the vein with forceps.

• Insert catheter filled with saline (to prevent air embolism).

• Advance slowly until free blood return is obtained.

• For emergency use, low position (2–4 cm) acceptable until radiographic confirmation.

5. Confirmation of Position

• Aspirate blood freely (should not be pulsatile).

• X-ray (AP chest–abdomen) to confirm tip location:

  • High position: at T8–T9 (just above diaphragm).

  • Low position: at L3–L4 (below liver).

6. Secure Catheter

• Tie umbilical tape firmly around cord.

• Apply sterile dressing and tape catheter to abdomen.

• Connect to infusion system with 3-way stopcock.

7. Documentation

• Record catheter size, insertion length, date/time, and tip level on X-ray.

Complications

Early:

• Malposition → hepatic or portal vein perforation

• Air embolism

• Arrhythmia

• Bleeding or hematoma

• Infection (omphalitis, sepsis)

Late:

• Thrombosis or embolism

• Portal hypertension

• Hepatic necrosis

• Catheter-related bloodstream infection

Prevention and Care

• Strict asepsis

• Confirm tip location before infusion of irritants

• Daily check for signs of infection or leakage

• Remove within 7–10 days (preferably <5 days)

Radiologic Tip Positions

Key Notes

• Never use arterial catheter for IV infusion — risk of gut necrosis.

• Flush catheter with saline to confirm patency before use.

• If resistance is met → stop and recheck direction; never force insertion.

• In case of doubt, remove and reattempt under sterile precautions.

Raised Intracranial Pressure (ICP)

1. Introduction and Definitions

• Definition: Abnormally high pressure within the rigid, non-compliant skull cavity.

• Normal ICP Range: to $15\text{ mmHg}$ (Supine adult). Pressures $>20\text{ mmHg}$ are generally considered pathological and require intervention.

• The Monro-Kellie Doctrine: States that the total volume within the cranial vault is fixed and is comprised of three components:

  • Brain Parenchyma ($\sim 80\%$)

  • Cerebrospinal Fluid (CSF) ($\sim 10\%$)

  • Intracranial Blood ($\sim 10\%$)

• 

  Compensation: An increase in the volume of one component must be offset by a decrease in one or both of the other components to maintain a stable ICP.

  • Initial compensation primarily involves displacement of CSF into the spinal subarachnoid space and compression of cerebral veins.

2. Pathophysiology and Mechanisms

• Pressure-Volume Curve (Compliance):

  • High Compliance (Initial Phase): Small increases in volume cause minimal change in ICP (flat part of the curve) due to compensatory mechanisms.

  • Low Compliance (Decompensation): Once compensation is exhausted, the curve becomes steep; a small increase in volume causes an exponential increase in ICP.

• Cerebral Perfusion Pressure (CPP): The net pressure gradient causing blood flow to the brain. Maintenance is critical for preventing secondary brain injury.

  • Formula: $CPP=MAP-ICP$ (Mean Arterial Pressure minus Intracranial Pressure).

  • Goal: Maintain $CPP$ typically $>60\text{ mmHg}$. If $ICP$ increases, $CPP$ decreases, leading to ischemia.

• Causes of Raised ICP:

  • Mass Lesions: Tumors (primary/metastatic), hematomas (epidural, subdural, intracerebral), cerebral abscesses.

  • Cerebral Edema:

    • Vasogenic: Breakdown of the blood-brain barrier (e.g., tumors, infection, trauma).

    • Cytotoxic: Cellular swelling due to ischemia (e.g., stroke, hypoxia, DKA).

  • Hydrocephalus: Impaired CSF flow or absorption (e.g., subarachnoid hemorrhage, meningitis, obstruction of the aqueduct of Sylvius).

  • Increased CBV: Hypercapnia (CO2 retention causes vasodilation), venous outflow obstruction (e.g., jugular vein thrombosis, position).

  • Idiopathic: Pseudotumor Cerebri (Idiopathic Intracranial Hypertension).

3. Clinical Features

4. Diagnosis and Monitoring

• Neuroimaging (Initial):

  • CT/MRI: Essential to identify underlying cause (mass lesion, hemorrhage, edema, hydrocephalus) and signs of herniation.

  • Warning: Lumbar Puncture (LP) is ABSOLUTELY CONTRAINDICATED in the presence of a known or suspected mass lesion or signs of herniation, as it can precipitate transtentorial or tonsillar herniation.

• ICP Monitoring (Gold Standard):

  • External Ventricular Drain (EVD): Provides continuous ICP measurement, allows sampling of CSF, and permits therapeutic drainage of CSF to lower ICP.

  • Fiber Optic Transducers: Devices placed in the parenchyma or subdural space.

5. Management (Tiered Approach)

The primary goal is to maintain $CPP>60\text{ mmHg}$ and $ICP<20\text{ mmHg}$.

Tier 0: General and Supportive Measures

• Positioning: Head of bed elevation to $30$ degrees (promotes venous outflow).

• Vitals: Maintain Normothermia (fever increases metabolism and ICP). Treat pain and agitation (sedation/analgesia).

• Hemodynamics: Maintain normovolemia and $MAP$ (to support $CPP$).

Tier 1: First-Line Therapies

• CSF Drainage: If an EVD is in place, initiate continuous or intermittent CSF drainage.

• Hyperosmolar Therapy: Creates an osmotic gradient to draw water out of the brain parenchyma into the intravascular space.

  • Mannitol ($0.25$ to $1.0\text{ g/kg}$ IV bolus): Requires intact blood-brain barrier (BBB) and maintenance of serum osmolarity $<320\text{ mOsm/L}$.

  • Hypertonic Saline (e.g., $3\%$ or $23.4\%$): Draws fluid from brain, increases $MAP$, and avoids the rebound ICP effect sometimes seen with Mannitol.

Tier 2: Second-Line Therapies (If ICP remains

$>20\text{ mmHg}$)

• Ventilation: Controlled, transient hyperventilation (Target pCO230−35 mmHg). Causes cerebral vasoconstriction, rapidly reducing $CBV$ and $ICP$. Use cautiously as it can cause ischemia.

• Diuresis: Repeat hyperosmolar therapy.

Tier 3: Third-Line Therapies (Refractory ICP)

• Barbiturate Coma (e.g., Pentobarbital): Decreases cerebral metabolic rate and $CBV$ (powerful vasoconstrictor). Requires continuous $EEG$ monitoring and full $ICU$ support.

• Decompressive Craniectomy: Surgical removal of a portion of the skull to allow the edematous brain to swell outward, physically reducing pressure.

• Hypothermia: Induced mild hypothermia (Controversial; used in select, severe cases).

6. Complications

• Cerebral Herniation: Life-threatening displacement of brain tissue due to severe pressure gradient.

• Uncal Herniation: Medial temporal lobe (uncus) through the tentorial notch. Causes ipsilateral fixed and dilated pupil (CN III compression) and contralateral hemiparesis.

• Tonsillar Herniation: Cerebellar tonsils through the foramen magnum. Compresses the brainstem, leading to cardiorespiratory arrest.

• Secondary Brain Injury: Ischemia and infarction caused by critically low $CPP$.

• Central Diabetes Insipidus/SIADH/Cerebral Salt Wasting: Endocrine/electrolyte disturbances often associated with severe brain injury.